Maple Tree Counselling Powers Mental Health Breakthrough in Hong Kong with Expansive Therapy Services for Individuals, Couples, Families, and Corporates
From one-on-one counselling and trauma therapy to family conflict resolution, couples work, and high-impact corporate wellness programmes, Maple Tree Counselling is quickly becoming the go-to hub for those seeking clarity, connection, and growth in their personal and professional lives.
With a stellar team of internationally trained, culturally attuned therapists, the practice delivers sessions in English, Cantonese, and Mandarin, serving Hong Kong's local and global communities with equal commitment and care.
At the heart of Maple Tree's success is its broad and flexible service offering. Whether it's an overwhelmed teenager, a high achieving executive facing burnout, or a couple struggling to reconnect, Maple Tree Counselling meets each client exactly where they are – with personalised strategies grounded in compassion and evidence-based practice.
Anjali Nihalchand, Co-founder and Director of Maple Tree Counselling, says of couples therapy, "A non-judgmental third party can be invaluable in getting to the heart of the issue and enabling you to get your needs met without overwhelming conflict. It may not always be comfortable, especially with emotionally triggering topics such as infidelity, however, the client will learn not only how to navigate roadblocks and issues within their relationship, but also how to soothe and emotionally regulate themselves in order to identify what they really want from their partner in their life together."
Maple Tree practitioners also provide individual therapy for adults and adolescents dealing with anxiety, depression, grief, trauma, career stress, and more. Couples and family therapy, including relationship facilitation, parenting support, and conflict resolution, are other areas where they can help. Group therapy sessions focused on shared challenges, personal growth, and community building, as well as corporate mental health solutions like on-site counselling and full-scale well-being strategies are other avenues of practice.
With skyrocketing demand from the business sector, Maple Tree has emerged as a top choice for mental health and wellness solutions in the corporate world. The practice collaborates with HR departments, team leads, and executives to roll out strategic programmes that promote emotional resilience and psychological safety at work.
These offerings include mental health check-ins for staff, custom workshops on stress management, emotional intelligence, and leadership wellness; as well as webinars and psychoeducation tailored to specific team needs; and on-site counselling services for confidential employee support.
As previously mentioned, what sets Maple Tree Counselling apart is its diverse, globally trained team, all of whom bring both clinical expertise and rich life experience to their work. With therapists fluent in English, Cantonese, and Mandarin, the practice makes therapy accessible to Hong Kong's international business professionals, returning locals, and multicultural couples and families.
Specialisations across the team include Cognitive Behavioural Therapy (CBT), Eye Movement Desensitization and Reprocessing (EMDR), somatic therapy, and mindfulness-based interventions, giving clients access to modern, effective approaches that align with their goals.
In addition to the above, a new couples counsellor joins the team in July, Julia Laubscher. Julia specializes in helping individuals and couples navigate challenges such as depression, anxiety, trauma, grief, and inner child wounds. She has a particular focus on couples counselling, addressing relationship issues like conflict management, communication patterns, loss of connection and betrayal.
As the mental health conversation continues to evolve in Asia, Maple Tree Counselling is leading the charge. By removing the stigma around therapy and offering sophisticated, multilingual services across the personal and corporate spheres, the practice is helping shape a healthier, more self-aware Hong Kong.Therapists who already work with Maple Tree include co-founders Jacquelyn Tryde, Casey McGrath, Simon Westcott, and Associate therapists including Nicola Shannon, John Mok-Lamme, Amanda Friday, Josephine Tong, Kari Entwisle, Marilyn Tryde and Bea Smith.. To learn more, visit https://www.mapletreecounselling.com
###
For more information about Maple Tree Counselling, contact the company here:Maple Tree CounsellingAnjali Nihalchand +852 6375 6098info@mapletreecounselling.com19th Floor, China Building, 29 Queen's Road Central, Central, Hong Kong
CONTACT: Anjali Nihalchand
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
New York Post
4 minutes ago
- New York Post
Trump confirms possible China trip, but insists ‘not seeking' Xi summit
President Trump has revealed that he may jet over to China in the near future, but rebuffed suggestions that he is seeking a summit with Beijing counterpart Xi Jinping amid intense trade negotiations between the two economic superpowers. 'The Fake News is reporting that I am SEEKING a 'Summit' with President Xi of China. This is not correct, I am not SEEKING anything!' Trump wrote on Truth Social late Monday from Scotland, where he wrapped up a five-day visit Tuesday. 'I may go to China, but it would only be at the invitation of President Xi, which has been extended. Otherwise, no interest! Thank you for your attention to this matter.' Staffers for Trump and Xi have held discussions about setting up a meeting between the two leaders, potentially on the sidelines of the annual Asia-Pacific Economic Cooperation (APEC) meeting in South Korea, which takes place Oct. 30-Nov. 1, Reuters reported last week. It is unclear whether any discussions of Trump traveling to China directly have been broached. 3 President Trump confirmed ongoing talks with China about him meeting with leader Xi Jinping. Xinhua News Agency via Getty Images 3 President Trump and Chinese leader Xi Jinping's last in-person meeting took place in 2019. XinhuaTrump and Xi last met face-to-face in June 2019 on the sidelines of the G-20 summit in Osaka, Japan. The US and China have until Aug. 12 to reach a full-fledged trade agreement following a months-long truce that has seen duties temporarily come down from up to 145% on Chinese exports to the US and 125% on American goods. Negotiators from Washington and Beijing are holding a third round of talks this week in Stockholm. 'We have a good relationship with China,' Trump told reporters Monday at his Turnberry club on the west coast of Scotland. 'China's tough.' In 2024, China was the third-largest US trading partner among individual nations — behind only Mexico and Canada — with trade between the two nations amounting to $582.4 billion. Further complicating negotiations is Trump's looming threat to impose secondary tariffs of 100% against countries that trade with Moscow until the Kremlin ends its invasion of Ukraine and agrees a peace deal. China and India, in particular, have continued to purchase energy from Russia throughout the 41-month-old war on Ukraine. China has also been accused of providing Moscow's arms industry with critical supplies. 3 The Trump administration is currently involved in trade negotiations with China. Getty Images Beyond trade tensions, US officials have repeatedly warned about Chinese cyber attacks, such as the Salt Typhoon operation that breached American telecommunications systems. On Monday, the Financial Times reported that the Trump administration blocked Taiwanese President Lai Ching-te from stopping in New York City during a planned diplomatic visit to Central America later this year. China has long claimed sovereignty over the island state of Taiwan, which has its own currency, military and government. The US adheres to the One China Policy on paper, which acknowledges Beijing's claim, but takes no position on it.
Yahoo
32 minutes ago
- Yahoo
SergeFerrari Group: Revenue of €178.7 Million in the First Half of 2025
Continued sales momentum in the 2nd quarter of 2025 Growth exceeds 10% in the first six months of 2025 SAINT-JEAN-DE-SOUDAIN, France, July 29, 2025--(BUSINESS WIRE)--Regulatory News: SergeFerrari Group (FR0011950682 – SEFER), SergeFerrari Group (FR0011950682 - SEFER), a leading global supplier of innovative flexible composite materials, listed on Euronext Paris – Compartment C, today announced its revenues for the first half of 2025. Breakdown of sales by geographic area (unaudited) (€ thousands) 2ndquarter2025 2ndquarter2024 Ch. atcurrentscope andexchangesrates Ch. atconstantscope andexchangesrates H1 2025 H1 2024 Ch. atcurrentscope andexchangesrates Ch. atconstantscope andexchangesrates Europe 69,068 66,730 +3.5% +3.2% 128,589 120,519 +6.7% +6.5% Americas 14,979 8,325 +79.9% +86.4% 23,399 16,003 +46.2% +48.7% Asia – Africa – Pacific 15,512 13,387 +15.9% +16.0% 26,743 25,382 +5.4% +5.4% Total revenues 99,558 88,442 +12.6% +13.0% 178,731 161,904 +10.4% +10.5% Sébastien Baril, SergeFerrari Group's chairman of the Executive Board, stated: "Signs of improvement in our historic markets are gradually materializing. Serge Ferrari recorded an increase in revenues of over 10% in the first half of the year. This performance encourages us to continue our efforts to increase our operating leverage, our customer service and the flexibility of our cost structure in an environment where adaptability and responsiveness remain key." Q2 2025 activity The Group reported revenue of €99.6 million in the 2nd quarter of 2025, up 12.6% on a current scope and exchange rate basis, and up 13.0% on a constant scope and exchange rate basis compared with the same period last year. This change is due to: A currency effect of -0.4 %; A volume effect of -3.0%, due mainly to a fall in volumes of modular structures, for which the end markets are declining; A favorable price-mix effect of +16.0%, driven by a confirmed recovery in activities that have traditionally been profitable for the Group, such as Solar Protection and the new Solutions business lines, as well as the impact of price increases introduced to mitigate the negative effect of high inflation on certain raw materials. H1 2025 activity The Group posted sales of €178.7 million in the first half of 2025, up by more than 10% on both current and constant scopes and exchange rates. Half-year sales trends by geographical region are as follows: Europe posted solid revenue growth of 6.7% on a current scope and exchange rate basis and 6.5% on a constant scope and exchange rate basis, with sales of almost €129 million over the period, thanks to historic markets that remain well oriented. After a difficult 2024 exercise in North American markets, sales in the Americas rebounded strongly in the first half. Growth accelerated sharply between the 1st and 2nd quarters, taking half-year sales up to €23.4 million, representing growth at constant scope and exchanges rates of +49%. Sales in the Asia-Africa-Pacific region were up 5.4% on H1 2024, both on a current and constant scope and exchange rates basis, due to good momentum in the various markets. Outlook Based on a seasonal history between the first (driven by solar protection activity and tense architecture) and the second half of the fiscal year, the group will focus (despite an uncertain context, particularly on the geopolitical level) on maintaining its trajectory initiated with Transform 2025 that aims at increasing its adaptability and profitability. Financier calendar Publication of first half 2025 results on September 10, 2025, after market close. ABOUT SERGEFERRARI GROUP The Serge Ferrari Group is a leading global supplier of composite materials for Tensile Architecture, Modular Structures, Solar Protection and Furniture/Marine, in a global market estimated by the Company at around €6 billion. The unique characteristics of these products enable applications that meet the major technical and societal challenges: energy-efficient buildings, energy management, performance and durability of materials, concern for comfort and safety together, opening up of interior living spaces etc. Its main competitive advantage is based on the implementation of differentiating proprietary technologies and know-how. The Group has manufacturing facilities in France, Switzerland, Germany, Italy and Asia. Serge Ferrari operates in 80 countries via subsidiaries, sales offices and a worldwide network of over 100 independent distributors. At the end of 2024, SergeFerrari Group posted consolidated revenues of €323.6 million, more than 80% of which was generated outside France. SergeFerrari Group is listed on Euronext Paris – Compartment C (ISIN code: FR0011950682). SergeFerrari Group shares are eligible for the PEA-PME and FCPI investment schemes. View source version on Contacts Valentin Chefson Head of Relations Investisseursinvestor@ NewCap Investor Relations – Financial Communication Théo MartinTel. : 01 44 71 94 94sferrari@
Yahoo
4 hours ago
- Yahoo
Bausch Health to Acquire DURECT Corporation, Strengthening Commitment to Developing Innovative Solutions for Patients with Liver Disease
DURECT's lead asset, Larsucosterol, is an epigenetic modulator with FDA Breakthrough Therapy Designation Potential to be the first FDA-approved therapeutic option for the treatment of patients with alcoholic hepatitis Proposed acquisition strengthens Bausch Health's commitment to hepatology and patients suffering with liver disease complications globally LAVAL, QC and CUPERTINO, Calif., July 29, 2025 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE: BHC) (TSX: BHC), a global, diversified pharmaceutical company, and DURECT Corporation (NASDAQ: DRRX) today announced a definitive agreement under which Bausch Health will indirectly acquire DURECT Corporation, including a novel therapeutic molecule, larsucosterol, which can harness the power of epigenetic modulation. Larsucosterol, an endogenous sulfated oxysterol and an epigenetic modulator, has demonstrated promising results for the treatment of alcoholic hepatitis (AH) in Phase 2 trials. Bausch Health's hepatology development and commercial capabilities are well-suited to support the clinical development and potential commercialization of larsucosterol. AH is a life-threatening form of alcohol-associated liver disease (ALD), which can occur in individuals who chronically misuse alcohol. It is characterized by severe inflammation and destruction of liver tissue (i.e., necrosis). AH accounted for roughly 164,000 hospital admissions in the U.S. in 2021. There is currently no Food and Drug Administration (FDA) or European Medicines Agency (EMA) approved treatment for AH, and novel therapeutic strategies are needed to improve patient survival. "This announcement is fundamental progress on our Strategic Priority - Innovation, which is to intensify focus and operating rigor behind R&D and business development and demonstrates our commitment to hepatology and finding new ways to address unmet medical needs, living our purpose of enriching lives through our relentless drive to deliver better health outcomes for patients." said Thomas J. Appio, Chief Executive Officer, Bausch Health. "There is a significant unmet need in the treatment of patients with AH given the high mortality rate and that there are no currently approved treatments. We are very excited to add larsucosterol, an asset which has FDA Breakthrough Therapy Designation, to our pipeline, particularly as it builds on our existing expertise within the hepatology space. It is complementary to our ongoing Phase 3 program of soluble solid dispersion of rifaximin (rifaximin SSD) being studied in cirrhotic patients globally," stated Jonathan Sadeh M.D., as Executive Vice President, Chief Medical Officer and Head of R&D at Bausch Health. "AH, by our estimates, is responsible for about 100 deaths per day in the US and billions of dollars in healthcare costs," stated James E. Brown, D.V.M., President and CEO of DURECT. "Since we reported results from our Phase 2b AHFIRM clinical trial for larsucosterol in AH, our primary focus has been advancing larsucosterol towards the completion of clinical development. We chose this transaction with Bausch Health because we believe it provides significant value for our stakeholders, both immediately and in the long term, should larsucosterol be approved and achieve commercial success. We view Bausch Health as the right partner to advance larsucosterol due to their expertise in hepatology, commercial success with Xifaxan and experienced development team. We look forward to the potential impact larsucosterol could have for patients with AH and the medical community that cares for them. Thank you to our team at DURECT and our partners that have helped advance larsucosterol to this point." A registrational Phase 3 program to evaluate the safety and efficacy of larsucosterol for the treatment of patients with severe AH is being planned. The trial will be a randomized, double-blind, placebo-controlled, multi-center study. The primary endpoint will be 90-day survival. The trial design will incorporate feedback received from the FDA during a Type B meeting under Breakthrough Therapy Designation as well as learnings from the prior Phase 2b AHFIRM trial in AH. The acquisition of the clinical development program for larsucosterol in AH compliments the ongoing Bausch Health RED-C clinical program which is designed to assess the efficacy of a next generation therapeutic, rifaximin SSD, to delay onset of first overt hepatic encephalopathy (OHE) hospitalization and all-cause mortality. There are no medications globally approved for the primary prophylaxis and delay in decompensation to first episode of OHE in cirrhosis. Patient enrollment in two global Phase 3, randomized, double-blind, placebo-controlled studies is now complete with efficacy and safety results expected to be announced in early 2026. "The addition of larsucosterol to our pipeline is a strategic fit with our focus in hepatology and underscores our continued dedication to exploring and identifying new treatments for individuals who are suffering with liver disease and its complications," stated Aimee Lenar, Executive Vice President of US Pharma at Bausch Health. "We are excited to continue investment in bringing these breakthrough options to market, not just in the US, but also globally." Transaction Terms and Financial Considerations Under the terms of the definitive agreement, a wholly owned subsidiary of Bausch Health will commence a tender offer for all outstanding shares of DURECT Corporation. Under the terms of the definitive agreement, Bausch Health will pay $1.75 per share in an all-cash transaction for an upfront consideration of approximately $63 million at closing, with the potential for two additional net sales milestone payments of up to $350 million in the aggregate (subject to certain adjustments in respect of a retention plan) if the milestone is achieved before the earlier of the 10 year anniversary of the first commercial sale in the United States and December 31, 2045. The purchase price payable at closing represents a premium of approximately 191% to the 30-day volume-weighted average trading price of DURECT's common stock ended on July 28, 2025, the last trading day before the announcement of the transaction. This upfront consideration represents a premium of approximately 217% to the trading price of DURECT's common stock ended on July 28, 2025. The transaction is conditioned on a majority of the outstanding shares of DURECT Corporation's common stock being tendered into the tender offer and not withdrawn, as well as other customary closing conditions. The transaction is expected to close in the third quarter of 2025. Assuming the closing of the tender offer, Bausch Health will acquire any shares of DURECT not tendered into the tender offer through a merger of a wholly owned subsidiary with and into DURECT for the same per share consideration payable in the tender offer. Advisors Centerview Partners LLC is serving as exclusive financial advisor and Sullivan & Cromwell LLP is serving as legal advisor to Bausch Health. Locust Walk is serving as exclusive financial advisor and Orrick, Herington and Sutcliffe LLP is serving as legal advisor to DURECT. About Bausch HealthBausch Health Companies Inc. (NYSE: BHC) (TSX: BHC), is a global, diversified pharmaceutical company enriching lives through our relentless drive to deliver better health care outcomes. We develop, manufacture and market a range of products primarily in gastroenterology, hepatology, neurology, dermatology, dentistry, aesthetics, international pharmaceuticals and eye health, through our controlling interest in Bausch + Lomb Corporation. Our ambition is to be a globally integrated healthcare company, trusted and valued by patients, HCPs, employees and investors. Our gastroenterology business, Salix Pharmaceuticals, is one of the largest specialty pharmaceutical businesses in the world and has licensed, developed and marketed innovative products for the treatment of gastrointestinal diseases for more than 30 years. For more information about Salix, visit and connect with us on Twitter and LinkedIn. For more information about Bausch Health, visit and connect with us on LinkedIn. About DURECT CorporationDURECT Corporation (Nasdaq: DRRX) is a late-stage biopharmaceutical company pioneering the development of epigenetic therapies that target dysregulated DNA methylation to transform the treatment of serious and life-threatening conditions, including acute organ injury. Larsucosterol, DURECT's lead drug candidate, binds to and inhibits the activity of DNA methyltransferases, epigenetic enzymes that are elevated and associated with hypermethylation found in AH patients. Larsucosterol is in clinical development for the potential treatment of AH, for which the FDA has granted a Fast Track and a Breakthrough Therapy designation; MASH is also being explored. For more information about DURECT, please visit and follow us on X (formerly Twitter) at Forward Looking StatementsThis news release may contain forward-looking statements about the proposed transaction with DURECT (the "Transaction") and the future performance of Bausch Health (Bausch Health and DURECT, collectively, "the Parties"), which may generally be identified by the use of the words "anticipates," "hopes," "expects," "intends," "plans," "should," "could," "would," "may," "believes," "subject to" and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Actual results are subject to other risks and uncertainties that relate more broadly to the Parties' overall businesses, including those more fully described in the Parties' most recent annual reports on Form 10-K and detailed from time to time in the Parties' other filings with the U.S. Securities and Exchange Commission and, in the case of Bausch Health, the Canadian Securities Administrators, which factors are incorporated herein by reference. In addition, such risks and uncertainties include, but are not limited to, the following: uncertainties relating to the timing of the consummation of the proposed Transaction; the possibility that any or all of the conditions to the consummation of the Transaction may not be satisfied or waived; the failure to obtain requisite stockholder approval of DURECT, the effect of the announcement or pendency of the Transaction on Parties' ability to maintain relationships with customers, suppliers, and other business partners; the impact of the Transaction if consummated on Bausch's business, financial position and results of operations, including with respect to expectations regarding margin expansion, accretion and deleveraging; and risks relating to potential diversion of management attention away from the Parties' ongoing business operations. There can be no assurance that the conditions to closing the Transaction will be satisfied or that the tender offer and the Transaction will be consummated. Additional information regarding certain of these material factors and assumptions may be found in the Parties' filings described above as well as the filings made in connection with the Transaction described below. These forward-looking statements speak only as of the date hereof. The Parties undertake no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this news release or to reflect actual outcomes, unless required by law. Additional InformationThis news release is for information purposes only and not intended to be a recommendation to buy, sell or hold securities and does not constitute an offer for the sale of, or the solicitation of an offer to buy, securities in any jurisdiction, including the United States. At the time the tender offer is commenced, we will file, or will cause to be filed, tender offer materials on Schedule TO with the SEC and DURECT will file a Solicitation/Recommendation Statement on Schedule 14D-9 with the SEC, in each case with respect to the tender offer. THE TENDER OFFER MATERIALS (INCLUDING AN OFFER TO PURCHASE, A RELATED LETTER OF TRANSMITTAL AND OTHER OFFER DOCUMENTS) AND THE SOLICITATION/RECOMMENDATION STATEMENT, AS THEY MAY BE AMENDED FROM TIME TO TIME, WILL CONTAIN IMPORTANT INFORMATION THAT SHOULD BE READ CAREFULLY WHEN THEY BECOME AVAILABLE AND CONSIDERED BEFORE ANY DECISION IS MADE WITH RESPECT TO THE TENDER OFFER. Those materials and all other documents filed by, or caused to be filed by, BHC and DURECT with the SEC will be available at no charge on the SEC's website at The tender offer materials and related materials also may be obtained for free (when available) under the "Corporate Governance—SEC Filings" section of our investor website at and the Solicitation/Recommendation Statement and such other documents also may be obtained for free (when available) from DURECT under the "SEC Filings" section of DURECT's investor website at View original content to download multimedia: SOURCE DURECT Corporation Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
